Clinical Trials

Urinary Bladder Neoplasms

NCT05554328 2026-03-18

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

165 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05564377 2026-03-18

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

2,900 enrolled

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT01042379 2026-03-13

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT07018622 2026-03-11

DAPA-ARMOR

46 enrolled

Other solid neoplasm

Solid Tumors

NCT05188508 2026-03-06

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

57 enrolled

CNS

Glioma

NCT04090567 2026-03-05

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Breast Neoplasms

NCT03297606 2026-03-04

CAPTUR

720 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT05463848 2026-03-04

Surgical Pembro +/- Olaparib w TMZ for rGBM

78 enrolled

CNS

Glioblastoma

NCT07024784 2026-03-04

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

377 enrolled

Fallopian Tube Neoplasms, Neoplasms

NCT04683679 2026-02-17

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

34 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02693535 2026-02-13

TAPUR

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT05568550 2026-01-30

Pembro With Radiation With or Without Olaparib

64 enrolled

Prostatic Neoplasms

NCT05498272 2026-01-23

NePtune

32 enrolled

Prostatic Neoplasms

NCT05524935 2026-01-08

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

37 enrolled

Dermatologic

Uveal Melanoma

NCT05568212 2025-12-01

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

176 enrolled

Thoracic

Non-small-cell Lung Cancer Patients

NCT04644289 2025-10-03

WoO

Carcinoma, Ovarian Epithelial

NCT06245889 2025-09-23

NeoADAPT

30 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05093231 2025-09-18

Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

20 enrolled

Pancreatic Neoplasms

NCT03740893 2025-08-11

PHOENIX

119 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02029001 2025-08-07

MOST plus

900 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06441747 2025-07-29

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

40 enrolled

Cholangiocarcinoma

NCT05623319 2025-06-24

THOR

Thoracic

SCLC,Extensive Stage

NCT04515836 2025-05-06

Olaparib in Patients With HRD Malignant Mesothelioma

Other solid neoplasmThoracic

56 enrolled

Mesothelioma, Malignant, Lung Neoplasms, Mesothelioma

NCT05536128 2025-04-17

Post-CDK

64 enrolled

Advanced Breast Cancer

NCT06686030 2025-04-16

Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer

150 enrolled

Platinum-sensitive Ovarian Cancer

NCT05332561 2025-03-20

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

240 enrolled

Breast Neoplasms

NCT03786796 2025-03-13

ORCHID

20 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05200260 2025-02-10

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

220 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05222971 2025-01-28

OPTIMUM

62 enrolled

Biliary Tract Neoplasms

NCT06739395 2024-12-18

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

300 enrolled

Other solid neoplasm

Solid Tumor

NCT06607692 2024-10-21

LUPARPED

25 enrolled

CNSEndocrineNET

Adrenal Gland Neoplasms, Medulloblastoma, Meningioma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT03991832 2024-07-18

SOLID

58 enrolled

CNSGastrointestinal

Glioma, Cholangiocarcinoma

NCT06377267 2024-05-09

STROBE

100 enrolled

Ovarian Neoplasms

NCT06078787 2024-05-06

PALBOLA

16 enrolled

Pancreatic Neoplasms

NCT04825990 2022-04-07

POINT